Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients

American Journal of Psychiatry

Volumn 152, Issue 2, 1995, Pages 179-182

  Kronig, Michael H ^a   Munne, Rafael A ^b   Szymanski, Sally ^b   Safferman, Allan Z ^b   Pollack, Simcha ^b   Cooper, Thomas ^b   Kane, John M ^b   Lieberman, Jeffrey A ^b  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMOBARBITAL; CHLORAL HYDRATE; CHLORPROMAZINE; CLOZAPINE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DISCRIMINANT ANALYSIS; DRUG BLOOD LEVEL; DRUG RESPONSE; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RATING SCALE; SCHIZOIDISM; SCHIZOPHRENIA; SINGLE BLIND PROCEDURE;

EID: 0028877764     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.152.2.179     Document Type: Article

References (16)

1. Lieberman JA, Johns CA, Kane JM, Rai K, Pisciotta AV, Saltz BL, Howard A: Clozapine-induced agranulocytosis: non-cross-reactivity with other psychotropic drugs. J Clin Psychiatry 1988; 49:271-277
2. Safferman A, Lieberman JA, Kane JM, Szymanski S, Kinon B: Update on the clinical efficacy and side effects of clozapine. Schizophr Bull 1991; 17:247-261
3. Kane J, Honigfeld G, Singer J, Meltzer H: Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45:789-796
4. Casey DE: Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology (Berl) 1989; 99(suppl):S47-S53
5. Kane J, Cooper TD, Sachar EJ, Halpern FS, Bailine S: Clozapine: plasma levels and prolactin response. Psychopharmacology (Berl) 1981; 73:184-187
6. Ackenheil M, Brau H, Burkhart A, Franke A, Pacha W: Antipsychotic efficacy in relation to plasma levels of clozapine. Arzneim Forsch 1976; 26:1156-1158 (German; English abstract)
7. Brau H, Burkhart A, Pacha W, Ackenheil M: Relationships between effects and plasma levels of clozapine. Arzneim Forsch 1978; 28:1300 (German; English abstract)
8. Thorup M, Fog R: Clozapine treatment of schizophrenic patients: plasma concentrations and coagulation factors. Acta Psychiatr Scand 1977; 55:123-126
9. Perry PJ, Miller DD, Arndt SV, Cadoret RJ: Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry 1991; 148:231-235
10. Hasegawa M, Gutierrez-Esteinou R, Way L, Meltzer HY: Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking. Psychopharmacology (Berl) 1993; 13:383-390
11. Overall JE, Gotham DR: The Brief Psychiatric Rating Scale. Psychol Rep 1962; 10:799-812
12. Woerner MG, Mannuzza S, Kane JM: Anchoring the Brief Psychiatric Raring Scale: an aid to improve reliability. Psychopharmacol Bull 1988; 24:112-117
13. Guy W (ed): ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Rockville, Md, US Department of Health, Education, and Welfare, 1976
14. Simpson GM, Cooper TB: Clozapine plasma levels and convulsions. Am J Psychiatry 1978; 135:99-100
15. Haring C, Fleischhacker WW, Schett P, Humpel C, Barnas C, Saria A: Influence of patient-related variables on clozapine plasma levels. Am J Psychiatry 1990; 147:1471-1475
16. Haring C, Meise U, Humpel C, Saria A, Fleischhacker WW, Hinterhuber H: Dose related plasma levels of clozapine: influence of smoking behaviour, sex and age. Psychopharmacology (Berl) 1989; 99(suppl):S38-S40